{
    "clinical_study": {
        "@rank": "28346", 
        "arm_group": [
            {
                "arm_group_label": "Ipilimumab plus NY-ESO-1 OLP4 Vaccine with Montanide", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide ISA 51 VG s.c. every 3 weeks for 4 doses."
            }, 
            {
                "arm_group_label": "Ipilimumab plus NY-ESO-1 Protein Vaccine with Montanide", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 Protein mixed with Poly-ICLC and Montanide ISA 51 VG s.c. every 3 weeks for 4 doses."
            }, 
            {
                "arm_group_label": "Ipilimumab plus NY-ESO-1 OLP4 Vaccine without Montanide", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab i.v. over 90 minutes followed by NY-ESO-1 OLP4 mixed with Poly-ICLC s.c. every 3 weeks for 4 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and immunogenicity of\n      Ipilimumab i.v. followed by NY-ESO-1 Protein vaccine with Poly-ICLC and Montanide s.c. (Arm\n      A), or NY-ESO-1 OLP4 vaccine with Poly-ICLC and Montanide s.c. (Arm B), or NY-ESO-1 OLP4\n      vaccine mixed with Poly-ICLC without Montanide s.c.(Arm C)."
        }, 
        "brief_title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable or Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "This is a phase I, open-label, non-randomized study in 27 patients with unresectable or\n      metastatic melanoma, for whom treatment with ipilimumab is indicated.  Patients must have\n      evidence of NY-ESO-1 or LAGE-1 tumor positivity, radiologically measurable disease by\n      immune-related Response Criteria (irRC), and meet all other eligibility criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab\n             is indicated as per ipilimumab/Yervoy\u00ae package insert (applicable for US sites) or\n             product information (applicable for Australia site).\n\n          -  Radiologically measurable disease by immune-related Response Criteria (irRC).\n\n          -  Tumor expression of NY-ESO-1 or LAGE-1 antigen by IHC or RT-PCR, or evidence of\n             seropositivity to NY-ESO-1 or LAGE-1.\n\n          -  Willingness to provide at least one pre-and post-vaccination tumor biopsy sample.\n\n          -  Expected survival of at least 4 months.\n\n          -  At the time of day 1 of the study, patients must be at least 3 weeks since surgery.\n\n          -  At the time of day 1 of the study, patients with brain metastases must be\n             asymptomatic and: 1) at least 8 weeks without tumor progression after any whole brain\n             radiotherapy, 2) at least 4 weeks since craniotomy and resection or stereotactic\n             radiosurgery, 3) at least 3 weeks without new brain metastases as evidenced by MRI\n\n          -  ECOG performance status of 0-2.\n\n          -  The following laboratory parameters must be within the ranges specified: Hemoglobin \u2265\n             10 g/dL, Neutrophil count \u2265 1.5 x 109/L, Lymphocyte count \u2265 LLN Platelet count \u2265 80 x\n             109/L, Serum creatinine \u2264 2 mg/dL, Serum bilirubin \u2264 2 x ULN, AST/ALT \u2264 2 x ULN.\n\n          -  Have been informed of other treatment options.\n\n          -  Age \u2265 18 years.\n\n          -  Able and willing to give valid written informed consent.\n\n        Exclusion Criteria:\n\n          -  Any contraindications for ipilimumab/Yervoy\u00ae as per package insert(applicable for US\n             sites) or product information (applicable for Australia site).\n\n          -  Prior exposure to NY-ESO-1 vaccine.\n\n          -  Active autoimmune disease, symptoms or conditions except for vitiligo, type I\n             diabetes, treated thyroiditis, asymptomatic laboratory evidence of autoimmune disease\n             (e.g.: +ANA, +RF, antithyroglobulin antibodies), or mild arthritis requiring no\n             therapy or manageable with NSAIDs.\n\n          -  Unresolved immune related adverse events following prior biological therapy.\n\n          -  Systemic treatment with high dose corticosteroids (greater than Prednisone 10mg daily\n             or equivalent).\n\n          -  Metastatic disease to the central nervous system for which other therapeutic options,\n             including radiotherapy, may be available.\n\n          -  Myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or\n             transient ischemic attack, chest pain or shortness of breath with activity, or other\n             heart conditions being treated by a doctor.\n\n          -  Other malignancy within 3 years prior to entry into the study, except for treated\n             non-melanoma skin cancer and cervical carcinoma in situ.\n\n          -  Known immunodeficiency or HIV positivity, active Hepatitis B or active Hepatitis C.\n\n          -  History of severe allergic reactions to vaccines or unknown allergens.\n\n          -  Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding\n             disorders).\n\n          -  Participation in any other clinical trial involving another investigational agent\n             within 4 weeks prior to day 1 of the study.\n\n          -  Mental impairment that may compromise the ability to give informed consent and comply\n             with the requirements of the study.\n\n          -  Lack of availability for immunological and clinical follow-up assessments.\n\n          -  Women who are breast feeding or pregnant as evidenced by pregnancy test.\n\n          -  Women of childbearing potential not using a medically acceptable means of\n             contraception for the duration of the study.\n\n          -  Any condition that, in the clinical judgment of the treating physician, is likely to\n             prevent the patient from complying with any aspect of the protocol or that may put\n             the patient at unacceptable risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810016", 
            "org_study_id": "LUD2012-004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ipilimumab plus NY-ESO-1 OLP4 Vaccine with Montanide", 
                    "Ipilimumab plus NY-ESO-1 Protein Vaccine with Montanide", 
                    "Ipilimumab plus NY-ESO-1 OLP4 Vaccine without Montanide"
                ], 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": "Yervoy"
            }, 
            {
                "arm_group_label": "Ipilimumab plus NY-ESO-1 Protein Vaccine with Montanide", 
                "intervention_name": "NY-ESO-1 Protein Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Ipilimumab plus NY-ESO-1 OLP4 Vaccine with Montanide", 
                    "Ipilimumab plus NY-ESO-1 OLP4 Vaccine without Montanide"
                ], 
                "intervention_name": "NY-ESO-1 OLP4 Vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "NY-ESO-1", 
            "Metastatic Melanoma", 
            "Ipilimumab", 
            "Phase I", 
            "Adjuvant", 
            "Immunologic", 
            "Vaccination", 
            "Immunotherapy", 
            "Neoplasm"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jedd Wolchok, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Michael A Postow, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Philip Friedlander, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yvonne Saenger, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": [
                    {
                        "last_name": "Hassane M Zarour, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "John M Kirkwood, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville,", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia"
                }, 
                "investigator": {
                    "last_name": "Craig L Slingluff, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Austin Health, Ludwig Oncology Unit"
                }, 
                "investigator": {
                    "last_name": "Jonathan Cebon, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated.", 
        "overall_contact": {
            "email": "jjensen@licr.org", 
            "last_name": "Jessica D Jensen, MPH", 
            "phone": "212-450-1574"
        }, 
        "overall_official": [
            {
                "affiliation": "Memorial Sloan-Kettering Cancer Center", 
                "last_name": "Michael A Postow, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Pittsburgh", 
                "last_name": "Hassane M Zarour, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Virginia", 
                "last_name": "Craig L Slingluff, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability according to the National Cancer Institute CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 20 (+/-1)"
            }, 
            {
                "description": "Induction or augmentation of NY-ESO-1 specific immunity will be determined.", 
                "measure": "Immune Response", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 20 (+/- 1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810016"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tumor Response is defined as irCR, irPR or irSD over a period of at least 4 weeks as published by Wolchok et al.", 
                "measure": "Tumor Response by the immune-related Response Criteria (irRC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 13 and Week 20 (+/- 1)"
            }, 
            {
                "description": "Immunologic changes in the tumor microenvironment will be evaluated including patterns and extent of immune cell infiltrates, changes in chemokines and expression.", 
                "measure": "Tumor Microenvironment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 13"
            }
        ], 
        "source": "Ludwig Institute for Cancer Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ludwig Institute for Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}